Announcing the FDA approval of YCANTH™️ (cantharidin) topical solution 0.7% – 7/28/23

This email is being sent by on behalf of Verrica Pharmaceuticals Inc.

Please see Important Safety Information below and full Prescribing Information.

Announcing the FDA approval of YCANTH (cantharidin) Topical Solution 0.7%

For the treatment of molluscum contagiosum for patients 2 years of age and older.

Potential Billing Codes for YCANTH*

Code Type





Molluscum contagiosum



Destruction (e.g., laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin

tags or cutaneous vascular proliferative lesions up to 14 lesions



Destruction (e.g., laser surgery, electrosurgery, cryosurgery,

CPT 17111 chemosurgery, surgical curettement), of benign lesions other than skin

tags or cutaneous vascular proliferative lesions 15 or more lesions



Unclassified Drugs



Unclassified drug or Biologic; for use in hospital outpatient clinic or ambulatory surgery center

Available single use pre-filled applicator for YCANTH

Single Applicator NDC (Each)

Dosage Strength

WAC Per Applicator


0.7% (w/v)


YCANTH is available to providers directly via an exclusive distribution agreement with FFF Enterprises, Inc. or through our dedicated Pharmacy Provider, Nufactor®

Questions: please email


YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.


Important Safety Information



    • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes. 

    • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment. 

    • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.


The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.


No studies evaluating the drug interaction potential of cantharidin have been conducted.


Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.


Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis. 

Please see accompanying full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or Local skin reactions are expected and should be reported if they are severe.


*The information provided by Verrica regarding potential billing codes for YCANTH is for informational purposes only. It is not intended to constitute advice or be regarded as a substitute for advice. You should not rely upon the information as a basis for making any decisions and Verrica makes no representations or warranties about the completeness, accuracy, reliability, or suitability of the information. 


YCANTH and the YCANTH logo are registered trademarks of

Verrica Pharmaceuticals Inc.

©2023 July 2023 | US-YCN-00066D